30.42

11.35% 3.10

After Hours: 30.46 0.04 +0.13%

Mineralys Therapeutics Inc (MLYS)

Overview News Price History Option Chain Financials Discussions Forecast

Mineralys Therapeutics Inc stock is traded at $30.42, with a volume of 3.18M. It is up +11.35% in the last 24 hours and up +16.15% over the past month. Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.

Previous Close:

$27.32

Open:

$27.66

24h Volume:

3.18M

Relative Volume:

2.55

Market Cap:

$2.51B

Revenue:

Net Income/Loss:

$-154.65M

P/E Ratio:

-12.79

EPS:

-2.3786

Net Cash Flow:

$-142.43M

1W Performance:

+9.58%

1M Performance:

+16.15%

6M Performance:

-29.83%

1Y Performance:

+119.16%

1-Day Range:

$27.00

$31.11

1-Week Range:

$26.08

$31.11

52-Week Range:

$12.59

$47.65

Mineralys Therapeutics Inc Stock (MLYS) Company Profile

Name

Mineralys Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

(888) 378-6240

Address

150 N. RADNOR CHESTER RD., RADNOR

Employee

Twitter

Next Earnings Date

2026-03-12

Latest SEC Filings

MLYS's Discussions on Twitter

Compare MLYS vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MLYS Mineralys Therapeutics Inc	30.42	2.25B	0	-154.65M	-142.43M	-2.3786
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Mineralys Therapeutics Inc Stock (MLYS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-11-25	Initiated	Jefferies	Hold
Jul-10-24	Initiated	H.C. Wainwright	Buy
Apr-02-24	Initiated	Goldman	Buy
Mar-07-23	Initiated	BofA Securities	Buy
Mar-07-23	Initiated	Credit Suisse	Outperform
Mar-07-23	Initiated	Evercore ISI	Outperform
Mar-07-23	Initiated	Guggenheim	Buy
Mar-07-23	Initiated	Stifel	Buy
Mar-07-23	Initiated	Wells Fargo	Overweight

View All

Mineralys Therapeutics Inc Stock (MLYS) Latest News

Apr 13, 2026

Mineralys therapeutics MLYS: Chief medical officer sells $59k in shares - Investing.com India

Apr 13, 2026

Mineralys (MLYS) CMO exercises options and sells 2,170 shares under 10b5-1 plan - Stock Titan

Apr 13, 2026

Mineralys Therapeutics (NASDAQ: MLYS) insider sales and RSU vesting disclosed - Stock Titan

Apr 13, 2026

Affiliate sale of 14,058 shares and multiple David Rodman trades (MLYS) - Stock Titan

Apr 13, 2026

Apr 11, 2026

(MLYS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Apr 11, 2026

Apr 10, 2026

Sentiment Recap: Whats the profit margin of Mineralys Therapeutics Inc2026 Key Highlights & Daily Profit Maximizing Tips - baoquankhu1.vn

Apr 10, 2026

Aug Catalysts: What is Mineralys Therapeutics Incs revenue forecastQuarterly Portfolio Summary & Daily Oversold Bounce Ideas - baoquankhu1.vn

Apr 10, 2026

Apr 09, 2026

Retail Trends: What are the future prospects of Mineralys Therapeutics Inc2026 Sentiment & Community Shared Stock Ideas - baoquankhu1.vn

Apr 09, 2026

Mineralys Therapeutics (MLYS) Rule 144: Director sales and 2,170-share cashless exercise - Stock Titan

Apr 09, 2026

Apr 08, 2026

Form DEFA14A Mineralys Therapeutics, - StreetInsider

Apr 08, 2026

Mineralys Therapeutics (NASDAQ: MLYS) details 2026 virtual meeting, board elections - Stock Titan

Apr 08, 2026

Signal Recap: What are the future prospects of Mineralys Therapeutics Inc2026 Snapshot & Weekly High Return Stock Forecasts - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

Does Mineralys Therapeutics’ (MLYS) FDA Progress and Legal Hire Reshape Its Cardiorenal Commercialization Strategy? - Yahoo Finance

Apr 07, 2026

Mineralys Therapeutics' CEO Sold Shares Worth $1.97 Million. Should Investors Avoid the Stock? - Yahoo Finance

Apr 07, 2026

Apr 06, 2026

Profit Recap: Is Mineralys Therapeutics Inc impacted by rising ratesQuarterly Growth Report & Low Drawdown Trading Techniques - baoquankhu1.vn

Apr 06, 2026

Why Mineralys Therapeutics Stock Is Surging Today - TipRanks

Apr 06, 2026